Human circulating tumor DNA “was overall consistently shorter than the fragment length of normal cell-free DNA,” the authors wrote in their paper. The findings could help improve cancer diagnosis and ...

Improved methods for circulating tumor cell capture and analysis can ensure reproducible biomarker and omics insights across different cancer types. Mouadh Barbirou, is a molecular biologist at the ...

A McGill University-led research collaboration has achieved a breakthrough in understanding how cancer spreads. A clinical ...

In prostate cancer, reliable markers of disease status are important for selecting and monitoring treatment. Two recent studies have shown that increased levels of circulating cells predict worse ...

Circulating tumor cells comprise a heterogeneous group with biological properties often distinct from their primary tumor cell counterparts. Knowledge of the molecular architecture of CTCs is ...

Comparison of circulating tumor cell numbers before and after treatment is predictive for overall survival in patients with metastatic castration-resistant prostate cancer; this comparison is more ...

Liquid biopsy encompasses the analysis of several tumor-derived components found in body fluids, including cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and ...

“The discovery of cell-free, circulating tumor DNA (ctDNA) as a direct, albeit imperfect, measurement of tumor burden opens new possibilities for monitoring MRD and tailoring therapies accordingly.

Unlike traditional biopsies that require cutting or inserting a needle to remove a piece of the tumour, a liquid biopsy only ...

Monitoring of CTCs during and after adjuvant therapy may aid clinical management of the individual cancer patient ... monocytes from smaller melanoma cells, the CTCs isolated on the ISET filters ...